A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

Prior treatment

• Patients with known brain metastases, leptomeningeal carcinomatosis, and/or spinal cord compression. Participants with brain metastases that have been previously totally resected or irradiated are eligible provided no progression or relapse is observed within 4-weeks of the last treatment.
• Non-resolution of any prior treatment-related toxicity to Grade \<2, except for alopecia according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
• Major surgery within 4-weeks before first study treatment administration.
• Washout period of at least 3-weeks or 5 times the half-life, whichever is shorter, of any cancer therapy (including anticancer therapy, vaccination, or any investigational agent). For patients who received immunotherapy (including anti-programmed death-1 \[anti-PD-1\] therapy) a washout of at least a 4-week recovery period is required.
• Immunosuppressive corticosteroid doses (prednisone \>7.5 mg daily orally \[PO\] or intravenously \[IV\], or equivalent) within 2-weeks before the first dose of ConvitVax and maintenance therapy with prednisolone \>7.5 mg/day PO or equivalent during the study.
• Patients positive for Covid-19 or those who had the disease within a month before their inclusion in the study.
• Patients with previous or current active autoimmune disease requiring immunosuppressive treatment (e.g., inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, polymyositis, dermatomyositis, insulin-dependent diabetes mellitus \[IDDM\] or infant- juvenile diabetes, vasculitis syndrome, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis or other rheumatic diseases or any other related medical disorder.)
• Known or proven adverse reaction to vaccines, such as anaphylaxis or other severe reaction.
• Any prior organ transplant.
• Prior treatment with live, attenuated vaccines within 4-weeks before initiation of study intervention and during treatment.
• Active infections, including unexplained fever (temperature \>38.1°C), or antibiotics therapy within 1-week before enrollment.
• Previous enrollment in this study.

Other illness

• History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or active hepatitis A, B (defined as either positive HBsAg or negative HBsAg with positive HBc antibody), or C (defined as a known positive hepatitis C antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay) infection.
• Active infection that requires the continuous use of antibiotic therapy.

Lab values

• Inadequate hematological function including neutrophils \<1.5 × 109/L; hemoglobin ˂9 gr/dL, and platelet count \<100 × 109/L.
• Inadequate liver function test with total bilirubin ˃1.5 × upper limit of normal (ULN), unless Gilbert's syndrome (in which case, total bilirubin ˃2.5 × ULN or alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], or alkaline phosphatase \[ALP\] ˃2.5 × ULN in the absence of hepatic metastases). In the presence of hepatic metastases, total bilirubin ˂3 × ULN and ALT (or AST) ˂5 × ULN are acceptable. ALP ˂5 × ULN would be acceptable only if related to the presence of bone metastases, as judged by the investigator.
• Inadequate renal function with serum creatinine ≥1.5 × ULN or between 1.0 and 1.5 × ULN with estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 as estimated using the abbreviated Modification of Diet in Renal Disease formula.
• Inadequate coagulation test: prothrombin time (PT) or international normalized ratio (INR) value ˃1.5 × ULN. Patients with anticoagulant therapy are excluded. Patients with low dose aspirin (˂100 mg) and prophylactic low dose heparin are allowed.
• Patient is deemed unsuitable for participation, whatever the reason, as judged by the investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to the study procedures (e.g., unwilling and unable to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restriction).
• Presence of any significant and uncontrolled medical, psychiatric, chronic condition, or laboratory abnormalities that may denote a risk associated with the patient's participation in the study, or that may interfere with the interpretation of the results, as judged by the investigator.

Age

• Patients with any other cancer. However, adequately treated basal, squamous carcinoma of the skin or in situ cervical cancer, or any other cancer from which the patient has been disease free for \>3 years are allowed.

Other

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥1.
• Life expectancy \<3 months.
• Known or suspected contraindication to BCG and/or formalin.
• Current pregnancy or breastfeeding.
• Patients who had a splenectomy.
• Patients with known or suspected congenital immunodeficiency.
• Current participation in another clinical trial.
• Individuals accommodated in an institution because of regulatory or legal order; prisoners or subjects who are legally institutionalized.
• The patient is on the staff (or relative thereof) directly involved in the conduct of the protocol.

• Female patients who are ≥18 years of age at the time of signing the informed consent forms (ICFs).
• Histologically- or cytologically-confirmed diagnosis of adenocarcinoma of the breast.
• Female patients with evidence of either locally advanced (not amenable to radiation therapy or surgery in a curative intent), inoperable, and/or metastatic disease who have either progressed, recurred after standard of care treatment, have refused, or are otherwise ineligible for standard of care treatment.
• Measurable disease with bidimensional measurements of at least 1 × 1 cm.
• Patients with a ≤10 mm diameter PPD response of skin induration.
• For patients who consent to paired biopsies (before treatment and during treatment): for baseline samples, a formalin-fixed and paraffin-embedded (FFPE) archived biopsy sample can be used, but fresh biopsies from primary or recurrence or metastasis are preferred.
• Female patients must not be pregnant, breastfeeding, nor be planning a pregnancy during their participation in the study. The use of an effective contraceptive method is mandatory in patients capable of having children. It is known that avoiding sexual activity (true abstinence) is the only secure method to prevent pregnancy; however, when patients choose to be sexually active, the participant must agree to use an appropriate "double-barrier" contraceptive method (such as the use of a diaphragm, intrauterine device \[IUD\], or contraceptive sponge, as well as the use of condom) or pills, injections or implants prescribed for birth control.
• Ability to understand and willingness to sign written ICFs.